Meeting
2022 ASCO Annual Meeting
Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.
Authors
Deniz Can Guven
Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey
Deniz Can Guven , Nicolas Sayegh , Nishita Tripathi , Mustafa Erman , Neeraj Agarwal , Umang Swami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5079)
DOI
10.1200/JCO.2022.40.16_suppl.5079
Abstract #
5079
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi
Poster
2022 ASCO Annual Meeting
Indirect comparisons of triplet therapy as compared to novel hormonal therapy doublets in patients with metastatic castration sensitive prostate cancer.
First Author: Syed Arsalan Ahmed Naqvi
Poster
2021 ASCO Annual Meeting
Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.
First Author: Larissa Mendes
Poster
2016 Genitourinary Cancers Symposium
Chemotherapy in metastatic hormone-naïve prostate cancer: Pooled analysis of randomized clinical trials.
First Author: Paolo Fabbri